微管靶向剂:破坏细胞骨架作为卵巢癌治疗的支柱。
Microtubule-Targeting Agents: Disruption of the Cellular Cytoskeleton as a Backbone of Ovarian Cancer Therapy.
发表日期:2024
作者:
Michael Danziger, Helen Noble, Dana M Roque, Fuhua Xu, Gautam G Rao, Alessandro D Santin
来源:
PHARMACOLOGY & THERAPEUTICS
摘要:
微管是由 α- 和 β- 微管蛋白异二聚体组成的动态聚合物。微管在真核生物中普遍保守,参与几乎所有细胞过程,包括细胞内运输、复制、极性、细胞骨架形状和运动。由于它们在有丝分裂中的基本作用,它们代表了抗癌治疗的经典靶点。微管稳定剂目前是原发性和复发性卵巢癌最有效治疗方案的组成部分。不幸的是,耐药性的发展继续带来治疗挑战。了解微管活性药物抗性的潜在机制可能有助于开发针对这种疾病的新颖和改进方法。© 2024。Springer Nature Switzerland AG。
Microtubules are dynamic polymers composed of α- and β-tubulin heterodimers. Microtubules are universally conserved among eukaryotes and participate in nearly every cellular process, including intracellular trafficking, replication, polarity, cytoskeletal shape, and motility. Due to their fundamental role in mitosis, they represent a classic target of anti-cancer therapy. Microtubule-stabilizing agents currently constitute a component of the most effective regimens for ovarian cancer therapy in both primary and recurrent settings. Unfortunately, the development of resistance continues to present a therapeutic challenge. An understanding of the underlying mechanisms of resistance to microtubule-active agents may facilitate the development of novel and improved approaches to this disease.© 2024. Springer Nature Switzerland AG.